Elan restructures Tysabri collaboration with Biogen in $3.25bn deal
Biogen has agreed with Elan Corporation to take over the ownership of their multiple sclerosis drug Tysabri for $3.25bn.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news